REPLIGEN CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
REPLIGEN CORP (RGEN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $6.12 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2018-02-22
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-12-31 was $0.00.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-06-30 was $0.00.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2017-03-31 was $6.12M, a 36.58% increase year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2017 was $6.12M, a 27.99% increase from fiscal 2016.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2016 was $4.78M, a 319.75% increase from fiscal 2015.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2015 was $1.14M, a 8.61% decline from fiscal 2014.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2014 was $1.25M, a 7.08% decline from fiscal 2013.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $0.00 derived: sum of 2 quarters · filed 2018-02-22 | $0.00 derived: sum of 3 quarters · filed 2018-02-22 | $6.12M 10-K · filed 2018-02-22 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $6.12M 10-Q · filed 2017-11-09 | $6.12M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $6.12M 10-Q · filed 2017-08-03 | $6.12M derived: sum of 3 quarters · filed 2017-08-03 | $6.42M derived: sum of 4 quarters · filed 2017-08-03 |
| 2017-03-31 | $6.12M 10-Q · filed 2017-05-04 | $6.12M derived: sum of 2 quarters · filed 2017-05-04 | $6.42M derived: sum of 3 quarters · filed 2017-05-04 | $6.42M derived: sum of 4 quarters · filed 2017-05-04 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $301.00K derived: sum of 2 quarters · filed 2017-02-23 | $301.00K derived: sum of 3 quarters · filed 2017-02-23 | $4.78M 10-K · filed 2017-02-23 |
| 2016-09-30 | $301.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $301.00K derived: sum of 2 quarters · filed 2016-11-03 | $4.78M 10-Q · filed 2016-11-03 | $4.78M derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $4.48M 10-Q · filed 2016-08-04 | $4.48M derived: sum of 3 quarters · filed 2016-08-04 | $4.48M derived: sum of 4 quarters · filed 2016-08-04 |
| 2016-03-31 | $4.48M 10-Q · filed 2016-05-05 | $4.48M derived: sum of 2 quarters · filed 2016-05-05 | $4.48M derived: sum of 3 quarters · filed 2016-05-05 | $4.51M derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $1.26K derived: sum of 2 quarters · filed 2016-02-25 | $29.00K derived: sum of 3 quarters · filed 2016-02-25 | $1.14M 10-K · filed 2016-02-25 |
| 2015-09-30 | $1.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $29.00K derived: sum of 2 quarters · filed 2015-11-05 | $1.14M 10-Q · filed 2015-11-05 | $1.14M derived: sum of 4 quarters · filed 2015-11-05 |
| 2015-06-30 | $27.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.14M 10-Q · filed 2015-08-06 | $1.14M derived: sum of 3 quarters · filed 2015-08-06 | $1.27M derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | $1.11M 10-Q · filed 2015-05-08 | $1.11M derived: sum of 2 quarters · filed 2015-05-08 | $1.25M derived: sum of 3 quarters · filed 2015-05-08 | $2.28M derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $136.13K derived: sum of 2 quarters · filed 2015-03-17 | $1.17M derived: sum of 3 quarters · filed 2015-03-17 | $1.25M 10-K · filed 2015-03-17 |
| 2014-09-30 | $136.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.17M derived: sum of 2 quarters · filed 2014-11-07 | $1.25M 10-Q · filed 2014-11-07 | $1.25M derived: sum of 4 quarters · filed 2014-11-07 |
| 2014-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $1.11M 10-Q · filed 2014-08-11 | $1.11M derived: sum of 3 quarters · filed 2014-08-11 | $1.11M derived: sum of 4 quarters · filed 2014-08-11 |
| 2014-03-31 | $80.00K 10-Q · filed 2014-05-09 | $80.00K derived: sum of 2 quarters · filed 2014-05-09 | $80.00K derived: sum of 3 quarters · filed 2014-05-09 | $89.33K derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $0.00 derived: sum of 2 quarters · filed 2014-03-14 | $9.33K derived: sum of 3 quarters · filed 2014-03-14 | $1.34M 10-K · filed 2014-03-14 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $9.33K derived: sum of 2 quarters · filed 2013-11-08 | $1.34M 10-Q · filed 2013-11-08 | $1.34M derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-06-30 | $9.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $1.34M 10-Q · filed 2013-08-07 | $1.34M derived: sum of 3 quarters · filed 2013-08-07 | $1.34M derived: sum of 4 quarters · filed 2013-08-07 |
| 2013-03-31 | $1.33M 10-Q · filed 2013-05-07 | $1.33M derived: sum of 2 quarters · filed 2013-05-07 | $1.33M derived: sum of 3 quarters · filed 2013-05-07 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $35.00K 10-K · filed 2013-03-15 | |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $35.00K 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $35.00K 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |